Adrixetinib

N/A

Report date: 2026/01/16 10:34:30
NME

Base Information

Drug NameAdrixetinib
Drug Alias NameAxl/Mer/CSF1R triple InhibitorQ-702
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTyrosine-protein kinase Mer inhibitorsColony stimulating factor 1 receptor inhibitors
TargetsAXL receptor tyrosine kinaseColony stimulating factor 1 receptorTyrosine-protein kinase Mer
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmSolid tumoursCentral Nervous System Lymphoma +[26] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpainSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVichem ChemieMax Planck Institute of BiochemistryLead Discovery Center GmbH
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterQurient Co LtdMayo Clinic +[4] 
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmSolid tumoursCentral Nervous System Lymphoma +[25] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A